This is a 12 month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms, improving physical function and preserving bone structure in patients with active psoriatic arthritis and had inadequate response to a traditional, non-biologic disease modifying anti-rheumatic drug. Adalimumab is use as a comparator.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01877668?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
